FORESIGHT AUTONOMOUS-SP ADR (FRSX) Fundamental Analysis & Valuation

NASDAQ:FRSX • US3455232039

2.6777 USD
+0.12 (+4.8%)
Last: Mar 4, 2026, 03:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This FRSX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall FRSX gets a fundamental rating of 3 out of 10. We evaluated FRSX against 41 industry peers in the Automobile Components industry. No worries on liquidiy or solvency for FRSX as it has an excellent financial health rating, but there are worries on the profitability. FRSX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. FRSX Profitability Analysis

1.1 Basic Checks

  • In the past year FRSX has reported negative net income.
  • FRSX had a negative operating cash flow in the past year.
  • In the past 5 years FRSX always reported negative net income.
  • FRSX had a negative operating cash flow in each of the past 5 years.
FRSX Yearly Net Income VS EBIT VS OCF VS FCFFRSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • FRSX has a Return On Assets of -145.69%. This is amonst the worse of the industry: FRSX underperforms 95.12% of its industry peers.
  • FRSX's Return On Equity of -210.00% is on the low side compared to the rest of the industry. FRSX is outperformed by 85.37% of its industry peers.
Industry RankSector Rank
ROA -145.69%
ROE -210%
ROIC N/A
ROA(3y)-91.84%
ROA(5y)-66.89%
ROE(3y)-126.58%
ROE(5y)-88.71%
ROIC(3y)N/A
ROIC(5y)N/A
FRSX Yearly ROA, ROE, ROICFRSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • With an excellent Gross Margin value of 59.29%, FRSX belongs to the best of the industry, outperforming 97.56% of the companies in the same industry.
  • In the last couple of years the Gross Margin of FRSX has grown nicely.
  • The Profit Margin and Operating Margin are not available for FRSX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.09%
GM growth 5YN/A
FRSX Yearly Profit, Operating, Gross MarginsFRSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. FRSX Health Analysis

2.1 Basic Checks

  • FRSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for FRSX has been increased compared to 1 year ago.
  • The number of shares outstanding for FRSX has been increased compared to 5 years ago.
  • There is no outstanding debt for FRSX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FRSX Yearly Shares OutstandingFRSX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
FRSX Yearly Total Debt VS Total AssetsFRSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • FRSX has an Altman-Z score of -24.03. This is a bad value and indicates that FRSX is not financially healthy and even has some risk of bankruptcy.
  • FRSX's Altman-Z score of -24.03 is on the low side compared to the rest of the industry. FRSX is outperformed by 82.93% of its industry peers.
  • FRSX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.03
ROIC/WACCN/A
WACC8.58%
FRSX Yearly LT Debt VS Equity VS FCFFRSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • FRSX has a Current Ratio of 4.02. This indicates that FRSX is financially healthy and has no problem in meeting its short term obligations.
  • FRSX has a Current ratio of 4.02. This is amongst the best in the industry. FRSX outperforms 87.80% of its industry peers.
  • FRSX has a Quick Ratio of 4.02. This indicates that FRSX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.02, FRSX belongs to the top of the industry, outperforming 87.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 4.02
FRSX Yearly Current Assets VS Current LiabilitesFRSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. FRSX Growth Analysis

3.1 Past

  • FRSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.37%, which is quite good.
  • The Revenue for FRSX has decreased by -32.13% in the past year. This is quite bad
  • FRSX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 53.73% yearly.
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.5%
Revenue 1Y (TTM)-32.13%
Revenue growth 3Y53.73%
Revenue growth 5YN/A
Sales Q2Q%4.07%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FRSX Yearly Revenue VS EstimatesFRSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 100K 200K 300K 400K 500K
FRSX Yearly EPS VS EstimatesFRSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2020 2021 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. FRSX Valuation Analysis

4.1 Price/Earnings Ratio

  • FRSX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FRSX Price Earnings VS Forward Price EarningsFRSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRSX Per share dataFRSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FRSX Dividend Analysis

5.1 Amount

  • No dividends for FRSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FRSX Fundamentals: All Metrics, Ratios and Statistics

FORESIGHT AUTONOMOUS-SP ADR

NASDAQ:FRSX (3/4/2026, 3:04:12 PM)

2.6777

+0.12 (+4.8%)

Chartmill FA Rating
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobile Components
Earnings (Last)11-25
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner Change221.74%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap11.71M
Revenue(TTM)452.00K
Net Income(TTM)-12.46M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.91
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-3.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.59
FCFYN/A
OCF(TTM)-2.58
OCFYN/A
SpS0.1
BVpS1.36
TBVpS1.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -145.69%
ROE -210%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.29%
FCFM N/A
ROA(3y)-91.84%
ROA(5y)-66.89%
ROE(3y)-126.58%
ROE(5y)-88.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.09%
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 7.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 4.02
Altman-Z -24.03
F-Score3
WACC8.58%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)32.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.5%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.13%
Revenue growth 3Y53.73%
Revenue growth 5YN/A
Sales Q2Q%4.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.93%
OCF growth 3YN/A
OCF growth 5YN/A

FORESIGHT AUTONOMOUS-SP ADR / FRSX FAQ

What is the fundamental rating for FRSX stock?

ChartMill assigns a fundamental rating of 3 / 10 to FRSX.


What is the valuation status for FRSX stock?

ChartMill assigns a valuation rating of 0 / 10 to FORESIGHT AUTONOMOUS-SP ADR (FRSX). This can be considered as Overvalued.


What is the profitability of FRSX stock?

FORESIGHT AUTONOMOUS-SP ADR (FRSX) has a profitability rating of 1 / 10.


Can you provide the financial health for FRSX stock?

The financial health rating of FORESIGHT AUTONOMOUS-SP ADR (FRSX) is 7 / 10.